Careers  |  Sign In  |  Register  |   Twitter

HAE Therapy Trial Halted After Unexpected Antibodies

Bloomberg News reports that ViroPharma ended a mid-stage trial of a hereditary angioedema (HAE) therapy. The trial was for a “subcutaneous formulation of Cinryze,” a drug used “to prevent the swelling attacks” associated with the genetic disease. The trial, in the second of three phases, was halted when “some patients developed unexpected antibodies.” The company claims that it “hadn’t seen any adverse effects, and called the halt a precaution.” Halozyme Therapeutics, the drug-delivery systems developer, was also affected because its recombinant human hyaluronidase (rHuPH20) was combined with Cinryze as a part of the subcutaneous treatment.

Read the article published by Bloomberg News.